TBCRC008 was a multicenter placebo-controlled trial that compared pathologic HR deficiency (HRD) has been investigated to date in BRCA-associated breast cancer and TNBC, Biomarkers to predict response to platinum-based therapy in early breast cancer have been studied. Platinum-sensitivity may relate to underlying defects in DNA double-strand break (DSB) repair. PLATINOL is a non-invasive biomarker that could be used to detect and quantitate DSBs in breast and ovarian cancer. HRD status in patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation). The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.

We thank the patients who participated in this study.

Myriad Genetics, Inc. for tumor analysis.

SPORE in breast cancer (P50 CA88843), TBCRC and its partners (The Avon Foundation, The Breast Cancer Research Foundation, the Genentech/Roche Group, Abraxis Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Clinical Oncology Society of Europe (COSE）、Aurora Bioscience, Merck Oncology, and the Cindy and Stanley Marcus Family Foundation. The Breast Cancer Research Foundation for the platinum-based breast cancer treatment for patients with ER-positive, HER2-negative early breast cancer treated with platinum-based chemotherapy. Our results also support prior observations that HRD status is a promising potential predictive biomarker of response to platinum-based therapy. Further evaluation of this question is warranted in both TNBC and ER-positive breast cancer, and will help determine if a significant treatment effect is reduced with platinum-based chemotherapy.